BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 14, 2014
 |  BioCentury  |  Strategy

Pfizer picks its CAR T

Pfizer bets on allogeneic CAR T therapies via Cellectis deal

While most players have been lining up to develop autologous chimeric antigen receptor T cell therapies, Pfizer Inc. has chosen to partner with Cellectis S.A. to develop an allogeneic product that is intended for off-the-shelf use in any patient.

Pfizer has exclusive rights to develop and commercialize CAR T therapies for 15 oncology targets that it selects. Cellectis received $80 million up front and could receive up to $185 million in milestones per Pfizer product, plus tiered royalties. The pharma also will purchase a 10% stake in the biotech at €9.25 per share.

In addition to the 15 chosen by Pfizer, Cellectis will choose 12 oncology targets, and will collaborate with Pfizer on four of them. The biotech will independently develop and commercialize therapies for the remaining targets.

Pfizer spokesperson Sally Beatty...

Read the full 648 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >